Results 231 to 240 of about 113,580 (306)

Expansion of Splice-Switching Therapy with Antisense Oligonucleotides. [PDF]

Int J Mol Sci
Takeshima Y.
europepmc   +1 more source

Peptide–Oligonucleotide Conjugates: Catalytic Preparation in Aqueous Solution or On‐Column

Current Protocols, Volume 5, Issue 6, June 2025.
Abstract Peptide–oligonucleotide conjugates (POCs) are synthesized through a novel catalytic and sustainable approach. The amide coupling between peptide and oligonucleotide is facilitated by 1,4‐diazabicyclo[2.2.2]octane (DABCO) as catalyst and 2‐chloro‐4,6‐dimethoxy‐1,3,5‐triazine (CDMT) as a stoichiometric activating agent.
Marion Gras, Michael Smietana, Pauline Adler   +2 more
wiley   +1 more source

Epigenetic Regulation and Therapeutic Targeting of Alternative Splicing Dysregulation in Cancer. [PDF]

Pharmaceuticals (Basel)
Lei Y, Lai M.
europepmc   +1 more source

ASOBIOTICS 2024: an interdisciplinary symposium on antisense-based programmable RNA antibiotics. [PDF]

RNA
Vogel J, Faber F, Barquist L, Sparmann A, Popella L, Ghosh C.   +5 more
europepmc   +1 more source

Clinical potential of SAG-524: A novel HBV RNA destabilizer with a unique mechanism of action. [PDF]

Glob Health Med
Tanaka Y.
europepmc   +1 more source

Beyond Conventional Approaches: The Revolutionary Role of Nanoparticles in Breast Cancer

MedComm – Biomaterials and Applications, Volume 4, Issue 2, June 2025.
This review explores integrated approach of nanotechnology to breast cancer diagnosis and treatment. We highlight imaging techniques for tumor detection and biomarker analysis in biological samples for early diagnosis. Advanced therapies, including targeted drug delivery and antibody‐drug conjugates, enable precise medication transport to cancer cells,
Mohan Liu, Yusi Wang, Yan Li, Yibing Zhang, Bailing Zhou, Lei Yang, Xi Yan, Li Yang   +7 more
wiley   +1 more source

Application of 4'-C-α-aminoethoxy-2'-O-methyl-5-propynyl-uridine for antisense therapeutics. [PDF]

RSC Adv
Zhou Y, Sato H, Kawade M, Yamagishi K, Ueno Y.   +4 more
europepmc   +1 more source

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-895, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

mRNA Degradation as a Therapeutic Solution for Mucopolysaccharidosis Type IIIC: Use of Antisense Oligonucleotides to Promote Downregulation of Heparan Sulfate Synthesis. [PDF]

Int J Mol Sci
Santos JI, Gonçalves M, Almeida MB, Rocha H, Duarte AJ, Matos L, Moreira LV, Encarnação M, Gaspar P, Prata MJ, Coutinho MF, Alves S.   +11 more
europepmc   +1 more source

The Nasal–Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases

MedComm, Volume 6, Issue 6, June 2025.
Τhe BBB restricts CNS drug delivery. NBDD bypasses the BBB via olfactory/trigeminal routes, enabling CNS delivery of therapeutic (small molecules, biologics, nucleic acids) for neurodegenerative/psychiatric disorders and brain tumors using advanced NBDD delivery systems (e.g nanocarriers) to enhance targeting and bioavailability.
Yi Qiu, Shiyuan Huang, Li Peng, Li Yang, Guosong Zhang, Tao Liu, Fang Yan, Xi Peng   +7 more
wiley   +1 more source